← Health care and life sciences companies

    AdvanCell: company profile, size and contacts

    advancell.com.auActiveFor profit

    AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.

    Employees
    11-50
    Founded
    2019
    Total raised
    $14.6M
    Monthly visits
    282

    Company facts

    Website
    advancell.com.au
    Location
    Asia-Pacific (APAC), Australasia
    Employees
    11-50
    Founded
    2019 (7 years ago)
    Categories
    Biotechnology, Clinical Trials, Oncology, Pharmaceutical
    Company type
    For profit
    Listing
    Private
    Industry code (NAICS)
    6211 Offices of physicians; 3254 Pharmaceutical and medicine manufacturing
    Industry code (SIC)
    8000 Health services; 2834 Pharmaceutical preparations

    Funding

    Total raised
    $14.6M
    Funding rounds
    2
    Latest round
    Series B, 2022-08
    Investors
    2
    Lead investors
    2

    Web and app presence

    Monthly website visits
    282
    Global traffic rank
    #10,010,675
    Mobile apps
    3

    How AdvanCell compares

    • Size: AdvanCell has more employees than 15% of the 1251 health care and life sciences companies in our directory that report it.
    • Age: AdvanCell is older than 5% of the 1166 health care and life sciences companies in our directory that report it.
    • Web traffic: AdvanCell gets more monthly website visits than 13% of the 1233 health care and life sciences companies in our directory that report it.

    1282 health care and life sciences companies are in the directory, 519 of them in the same 11-50 employee range and 156 based in Asia-Pacific (APAC).

    Growth outlook

    • Trend: Growing

    AdvanCell may be growing as it has recently announced the dosing of the first patient in its Phase I/II TheraPb clinical trial, which is a significant milestone in the development of its Targeted Alpha Therapy platform technology. Additionally, the company has established a collaboration with POINT Biopharma to develop lead-212 labeled radioligands, indicating an expansion of its operations and partnerships within the biotechnology and oncology industries. Furthermore, AdvanCell's engagement with the AIBN's Centre for Advanced Imaging industry partner suggests active involvement in research and development, which could contribute to its growth trajectory.

    What AdvanCell says about itself

    “AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies.” advancell.com.au

    AdvanCell in short

    AdvanCell is a biotechnology company based in Asia-Pacific (APAC), with 11-50 employees, founded in 2019. Its website drew about 282 visits in the latest month measured and it has raised $14.6 million over 2 rounds.

    Frequently asked questions

    What does AdvanCell do?
    AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
    When was AdvanCell founded?
    AdvanCell was founded in 2019, so it is about 7 years old.
    How many employees does AdvanCell have?
    Crunchbase lists AdvanCell in the 11-50 employee range.
    Where is AdvanCell based?
    AdvanCell is listed under Asia-Pacific (APAC), Australasia.
    Has AdvanCell raised funding?
    Crunchbase records $14.6M raised across 2 funding rounds, most recently series b in 2022-08.
    How do I find email addresses at AdvanCell?
    Search the domain advancell.com.au with the Inbound Labs Domain Search or Email Finder to see verified contacts and departments. Individual addresses are shown after you sign up.

    Similar companies

    More in Health care and life sciences companies.

    Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.